key: cord-0843954-qc3gw2t6
authors: Olsen, Emily O'Malley; Roth, Nicole M.; Aveni, Kathryn; Santos, Pauline; Sizemore, Lindsey; Halai, Umme‐Aiman; Nestoridi, Eirini; Barton, Jerusha Elana; Mobley, Evan; Siebman, Samantha; Fussman, Chris; Mbotha, Deborah; Dzimira, Paula; Silcox, Kristin M.; Khuwaja, Salma; Roscom, Danacamile; Lush, Mamie; Chicchelly, Sarah; Delgado‐López, Camille; Schlosser, Levi; Read, Jennifer; Ellington, Sascha R.; Hall, Aron J.; Gilboa, Suzanne M.; Tong, Van T.; Woodworth, Kate R.
title: SARS‐CoV‐2 infections among neonates born to pregnant people with SARS‐CoV‐2 infection: Maternal, pregnancy and birth characteristics
date: 2022-04-18
journal: Paediatr Perinat Epidemiol
DOI: 10.1111/ppe.12883
sha: 9df136327f79e1dfd44f8758ecf4949ad13c41c2
doc_id: 843954
cord_uid: qc3gw2t6

BACKGROUND: Multiple reports have described neonatal SARS‐CoV‐2 infection, including likely in utero transmission and early postnatal infection, but published estimates of neonatal infection range by geography and design type. OBJECTIVES: To describe maternal, pregnancy and neonatal characteristics among neonates born to people with SARS‐CoV‐2 infection during pregnancy by neonatal SARS‐CoV‐2 testing results. METHODS: Using aggregated data from the Surveillance for Emerging Threats to Mothers and Babies Network (SET‐NET) describing infections from 20 January 2020 to 31 December 2020, we identified neonates who were (1) born to people who were SARS‐CoV‐2 positive by RT‐PCR at any time during their pregnancy, and (2) tested for SARS‐CoV‐2 by RT‐PCR during the birth hospitalisation. RESULTS: Among 28,771 neonates born to people with SARS‐CoV‐2 infection during pregnancy, 3816 (13%) underwent PCR testing and 138 neonates (3.6%) were PCR positive. Ninety‐four per cent of neonates testing positive were born to people with infection identified ≤14 days of delivery. Neonatal SARS‐CoV‐2 infection was more frequent among neonates born preterm (5.7%) compared to term (3.4%). Neonates testing positive were born to both symptomatic and asymptomatic pregnant people. CONCLUSIONS: Jurisdictions reported SARS‐CoV‐2 RT‐PCR results for only 13% of neonates known to be born to people with SARS‐CoV‐2 infection during pregnancy. These results provide evidence of neonatal infection identified through multi‐state systematic surveillance data collection and describe characteristics of neonates with SARS‐CoV‐2 infection. While perinatal SARS‐CoV‐2 infection was uncommon among tested neonates born to people with SARS‐CoV‐2 infection during pregnancy, nearly all cases of tested neonatal infection occurred in pregnant people infected around the time of delivery and was more frequent among neonates born preterm. These findings support the recommendation for neonatal SARS‐CoV‐2 RT‐PCR testing, especially for people with acute infection around the time of delivery.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to serious coronavirus disease 2019 in pregnant people, is associated with preterm birth and poses a potential risk of transmission to the neonate. [1] [2] [3] Reports have described perinatal infection, including likely in utero transmission and early postnatal infection. 3, 4 The American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC) recommend all neonates born to pregnant people with suspected or confirmed COVID-19 be tested for SARS-CoV-2 by real-time reverse transcription polymerase chain reaction (RT-PCR). 5, 6 Factors associated with infection among exposed neonates are unclear. We describe maternal, pregnancy and neonatal characteristics among a surveillance cohort of neonates born to people with SARS-CoV-2 infection during pregnancy and assess characteristics by reported neonatal SARS-COV-2 RT-PCR testing.

Pregnant people with laboratory-confirmed SARS-CoV-2 infection from 20 January to 31 December 2020 were retrospectively ascertained through reporting of pregnancy in COVID-19 surveillance and cross-matching COVID-19 surveillance data with local data systems to assess pregnancy status. The data are enhanced through supplemental data sources at the jurisdiction level such as vital statistics, administrative data sets, electronic laboratory reporting and maternal and neonatal medical record review and submitted to the Surveillance for Emerging Threats to Mothers and Babies Network (SET-NET). 7 SET-NET data contain maternal characteristics including demographics, prenatal history and SARS-CoV-2 infection (e.g. timing of infection and severity) as well as neonatal characteristics (e.g. gestational age and SARS-CoV-2 testing). This activity was reviewed by CDC and conducted consistent with applicable federal law and policy. 8 and Prevention. This work is supported by the Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases Cooperative Agreement (CK19-1904) and contractual mechanisms Objectives: To describe maternal, pregnancy and neonatal characteristics among neonates born to people with SARS-CoV-2 infection during pregnancy by neonatal SARS-CoV-2 testing results. Using aggregated data from the Surveillance for Emerging Threats to   Mothers and Babies Network (SET-NET) describing infections from 20 January 2020 to 31 December 2020, we identified neonates who were (1) born to people who were SARS-CoV-2 positive by RT-PCR at any time during their pregnancy, and (2) tested for SARS-CoV-2 by RT-PCR during the birth hospitalisation.

Results: Among 28,771 neonates born to people with SARS-CoV-2 infection during pregnancy, 3816 (13%) underwent PCR testing and 138 neonates (3.6%) were PCR positive. Ninety-four per cent of neonates testing positive were born to people with infection identified ≤14 days of delivery. Neonatal SARS-CoV-2 infection was more frequent among neonates born preterm (5.7%) compared to term (3.4%). Neonates testing positive were born to both symptomatic and asymptomatic pregnant people.

Jurisdictions reported SARS-CoV-2 RT-PCR results for only 13% of neonates known to be born to people with SARS-CoV-2 infection during pregnancy.

These results provide evidence of neonatal infection identified through multi-state systematic surveillance data collection and describe characteristics of neonates with SARS-CoV-2 infection. While perinatal SARS-CoV-2 infection was uncommon among tested neonates born to people with SARS-CoV-2 infection during pregnancy, nearly all cases of tested neonatal infection occurred in pregnant people infected around the time of delivery and was more frequent among neonates born preterm. These findings support the recommendation for neonatal SARS-CoV-2 RT-PCR testing, especially for people with acute infection around the time of delivery.

pregnancy, COVID-19, SARS-CoV-2, perinatal infection

Using aggregated SET-NET data compiled through 5 November 2021, we identified neonates who were (1) born to people who were SARS-CoV-2 RT-PCR positive in pregnancy, and (2) tested for SARS-CoV-2 by RT-PCR during the birth hospitalisation. For neonates with extended hospitalisation (>14 days) or whose date of discharge was unknown, only SARS-CoV-2 tests conducted ≤14 days following birth were included to focus on perinatal infections.

We described neonates by SARS-CoV-2 testing result. We focused on SARS-CoV-2-positive neonates and described maternal characteristics including demographics, COVID-19 disease severity 9 and timing of prenatal infection relative to delivery (determined by date of first positive SARS-CoV-2 or symptom onset if testing date was missing), pregnancy complications (e.g. preeclampsia), gestational age and birthweight. We also described these characteristics among neonates who were tested by SARS-CoV-2 RT-PCR following birth but who tested negative. Because negative results are not reported consistently to all jurisdictions, the group of test-negative neonates may not represent all neonates testing negative. Therefore, we did not perform statistical comparisons between neonates testing positive and negative for SARS-CoV-2. We compared testing status by maternal, birth and neonatal characteristics, including prevalence ratios for neonatal testing adjusted for jurisdiction and days from positive to delivery ( Table 2 ). Table 1 . Of SARS-CoV-2 positive neonates with date of maternal infection reported (n = 136), 94.1% were born to people with initial positive testing or symptom onset occurring ≤14 days before delivery and eight neonates were born to people with initial positive SARS-CoV-2 testing >14 days before delivery. Four of these persons remained SARS-CoV-2 positive within 2 days prior to delivery. Per cent positivity among neonates tested for SARS-CoV-2 was 1.1%, 2.5%, 4.1% and 4.6% for those born to people with infection diagnosed >14, 7-14, 3-6 and 0-2 days before delivery respectively. Of neonates testing positive and whose maternal disease severity was known, 47.8% were born to people reported as asymptomatic at COVID-19 diagnosis. Compared to neonates with no testing data reported, tested neonates were more likely to be born to people who were of non-White non-Hispanic race/ethnicity, with third trimester infection, infection ≤14 days before delivery, asymptomatic COVID-19 disease and caesarean delivery ( Table 2) . Compared to those without testing data, tested neonates were more likely to be born preterm or low birthweight, or have a neonatal intensive care unit admission.

Among the 138 neonates testing positive for SARS-CoV-2, 52.6% were female, 5.3% were small for gestational age (<10 th percentile by INTERGROWTH-21st) and 23.9% were born preterm (i.e. 

This study provides a description of SARS-CoV-2 testing patterns among neonates and evidence of neonatal infection identified through multi-state systematic surveillance. Figure S1 ). Timing of testing was similar for neonates testing negative for SARS-CoV-2. Additionally, we were unable to assess route of transmission (e.g.

in utero and peripartum), given lack of immunoglobulin-M serology and RT-PCR testing data on sterile specimens (e.g. blood). 13 Lastly, we could not assess infection prevention and control (IPC) measures implemented. Hawaiian or Pacific Islander, and Asian, Non-Hispanic. These were combined because of small cell sizes that yielded unreliable estimates. f Includes cardiovascular disease, chronic hypertension, chronic lung disease, diabetes mellitus (type 1 or type 2), immunosuppression and obesity (body mass index ≥30 kg/m 2 ). g Inclusive of preeclampsia, eclampsia or HELLP (haemolysis, elevated liver enzymes and low platelet) syndrome. Does not include chronic hypertension. Hypertensive disorders of pregnancy were only considered underlying conditions for women with third trimester infection. h Categories of disease severity were based on modified National

Institute of Health and World Health Organization criteria as described in Galang et al. 9 Pregnant people were considered asymptomatic if reported as having an absence of symptoms using a symptom status variable rather than sole absence of individual symptoms reported. Criteria were applied to classify severity using submitted data including symptoms, intensive care unit admission, invasive ventilation, use of COVID-19 therapies, complications associated with COVID-19 and death. i Defined as weight <10th percentile for sex (presumed female if missing) and gestational age using the INTERGROWTH-21st online percentile calculator http://inter growt h21.ndog.ox.ac.uk. Some gestational ages were reported in completed weeks only (rather than in weeks and days). 

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). Of note, SET-NET does not collect data on sex or gender of the birthing individual. We use the term 'maternal' throughout this publication to describe characteristics of birthing individuals, although they may be of any gender.

We continue to work through the challenge of finding the most inclusive language that is clear and scientifically accurate.

The SET-NET data are not available at this time.

Emily O'Malley Olsen https://orcid.org/0000-0002-5312-7596

Van T. Tong https://orcid.org/0000-0002-3970-1440

Update: Characteristics of symptomatic women of reproductive age with laboratoryconfirmed SARS-CoV-2 infection by pregnancy status -United States

Birth and infant outcomes following laboratory-confirmed SARS-CoV-2 infection in pregnancy -SET-NET, 16 Jurisdictions

Maternal transmission of SARS-COV-2 to the neonate, and possible routes for such transmission: a systematic review and critical analysis

Analysis of SARS-CoV-2 vertical transmission during pregnancy

FAQs: management of infants born to mothers with suspected or confirmed COVID-19

Evaluation and management considerations for neonates at risk for COVID-19

A preparedness model for mother-baby linked longitudinal surveillance for emerging threats

Risk factors for illness severity among pregnant women with confirmed severe acute respiratory syndrome coronavirus 2 infection -Surveillance for Emerging Threats to Mothers and Babies Network, 29 state, local, and territorial health departments

Association of maternal perinatal SARS-CoV-2 infection with neonatal outcomes during the COVID-19 pandemic in Massachusetts

Association of maternal SARS-CoV-2 infection in pregnancy with neonatal outcomes

Point: uncertainty about estimating the risks of COVID-19 during pregnancy

Definition and categorization of the timing of mother-to-child transmission of SARS-CoV-2

Quarantine and testing strategies in contact tracing for SARS-CoV-2: a modelling study

COVID-19 vaccines while pregnant or breastfeeding

We thank the following persons for their contributions to this project: 

All authors have no conflicts of interest to disclose.

All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.